Aldeyra needs more Tranquility
A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
Aerie brushes off dry eye trial failure
Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Novartis sees hidden value in Xiidra
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
Go or no go? Johnson & Johnson awaits Spravato nod
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Deal hopes revive Reneuron
After years in the wilderness, the UK cell therapy specialist Reneuron could be about to seal a deal with a big US player.